Page 10 - reflections_dyslipidaemia_newsletter7_2024
P. 10
REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #7 2024
The authors note that although statins have proven to be addition of PCSK-9 inhibitors or bempedoic acid. With residual
of immense benefit in the prevention of clinical CVD, many hypertriglyceridaemia, icosapent ethyl can be added. Fibrates
patients fail to attain the low levels of LDL recommended in can be used to prevent acute pancreatitis in patients with severe
Dyslipidaemia
guidelines. Patients with diabetes fall into the high or very high hypertriglyceridaemia. Newer treatments in development,
CVD risk categories, therefore the upfront use of combination including apoC-III and ANGPTL3 inhibitors, that specifically
therapies, particularly a statin plus ezetimibe, is a rational target the reduction of apoB-containing lipoproteins may be
initial approach. Other combination approaches include the promising.
Graphic Abstract
The authors note that screening, assessment, and management of lipid and lipoprotein disorders in patients living with diabetes are
among the most important steps to reduce ASCVD events, as emphasized by evidence-based guidelines such as the European
Society of Cardiology/European Association for the Study of Diabetes (ESC/EASD) in 2020, the European Society of Cardiology
(ESC)/European Atherosclerosis Society (EAS) also in 2020, the American Heart Association (AHA)/American College of Cardiology
(ACC) Multisociety Guideline on the Management of Blood Cholesterol in 2018, with a subsequent paper that includes the
recommendations listed specifically for patients living with diabetes by the AHA/ACC in Diabetes Care in 2020.
TABLE OF CONTENTS
